---
figid: PMC7461616__ijms-21-05845-g001
figtitle: Targeting lipid metabolism of myeloid cells in cancer immunotherapy
organisms:
- Homo sapiens
- Mus musculus
- Candida dubliniensis
pmcid: PMC7461616
filename: ijms-21-05845-g001.jpg
figlink: pmc/articles/PMC7461616/figure/ijms-21-05845-f001/
number: F1
caption: 'Targeting lipid metabolism of myeloid cells in cancer immunotherapy. Pharmacological
  modulation of molecular regulators of lipid metabolism in tumor-associated macrophages
  (TAM), monocytic (M-) and granulocytic (PMN-) myeloid-derived suppressor cells (MDSC)
  showed efficacy in dampening tumor immunosuppression and improving cancer immunotherapies:
  immune checkpoint blockade; adoptive cell transfer; cytokines administration or
  modulation; cancer vaccines; reprogramming of polarized inflammation in myeloid
  cells. Abbreviations: LXR, liver X receptor; ACAT1, acetyl-CoA acetyltransferase
  1; COX2, cyclooxygenase 2; FATP2, fatty acid transport protein 1; PPARγ, peroxisome
  proliferator-activated receptor γ; PD-1, programmed-death protein 1; PD-L1, PD-1
  ligand; CTLA4, cytotoxic T-lymphocyte antigen 4; CPT1a, carnitine palmitoyltransferase
  1a; CAR T/M, chimeric antigen receptor T cell/Macrophage; TCR T, T cell receptor-engineered
  T cell; NK, natural killer; CB, cholesterol biosynthesis; IFN, interferon; STING,
  stimulator of interferon genes; TLR, Toll-like receptor; GM-CSF, granulocyte-macrophage
  colony-stimulator factor; FAS, fatty acid synthesis; MSR1, macrophage scavenger
  receptor 1; DC, dendritic cell; SIRP1α, signal regulatory protein 1α; CSF1, macrophage
  colony-stimulating factor; CSF1R, CSF1 receptor; PI3K, phosphoinositide 3-kinase;
  HDAC, histone deacetylases; C5aR, complement component 5 receptor; PDE5, phosphodiesterase
  5; COX2, cyclooxygenase 2; PGE2, prostaglandin E2; CCR5, chemokine receptor 5; ATRA,
  all-trans retinoic acid; TEV, tumor-derived extracellular vesicles; RTK, receptor
  tyrosine kinase. Text in brackets represents examples of drugs targeting the molecule
  or pathway of reference. Dashed arrows and question marks underline controversial
  or not fully clarified evidence.'
papertitle: 'Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid
  Cells at the Crossroad.'
reftext: Augusto Bleve, et al. Int J Mol Sci. 2020 Aug;21(16):5845.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.7858564
figid_alias: PMC7461616__F1
figtype: Figure
organisms_ner:
- Homo sapiens
- Mus musculus
redirect_from: /figures/PMC7461616__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7461616__ijms-21-05845-g001.html
  '@type': Dataset
  description: 'Targeting lipid metabolism of myeloid cells in cancer immunotherapy.
    Pharmacological modulation of molecular regulators of lipid metabolism in tumor-associated
    macrophages (TAM), monocytic (M-) and granulocytic (PMN-) myeloid-derived suppressor
    cells (MDSC) showed efficacy in dampening tumor immunosuppression and improving
    cancer immunotherapies: immune checkpoint blockade; adoptive cell transfer; cytokines
    administration or modulation; cancer vaccines; reprogramming of polarized inflammation
    in myeloid cells. Abbreviations: LXR, liver X receptor; ACAT1, acetyl-CoA acetyltransferase
    1; COX2, cyclooxygenase 2; FATP2, fatty acid transport protein 1; PPARγ, peroxisome
    proliferator-activated receptor γ; PD-1, programmed-death protein 1; PD-L1, PD-1
    ligand; CTLA4, cytotoxic T-lymphocyte antigen 4; CPT1a, carnitine palmitoyltransferase
    1a; CAR T/M, chimeric antigen receptor T cell/Macrophage; TCR T, T cell receptor-engineered
    T cell; NK, natural killer; CB, cholesterol biosynthesis; IFN, interferon; STING,
    stimulator of interferon genes; TLR, Toll-like receptor; GM-CSF, granulocyte-macrophage
    colony-stimulator factor; FAS, fatty acid synthesis; MSR1, macrophage scavenger
    receptor 1; DC, dendritic cell; SIRP1α, signal regulatory protein 1α; CSF1, macrophage
    colony-stimulating factor; CSF1R, CSF1 receptor; PI3K, phosphoinositide 3-kinase;
    HDAC, histone deacetylases; C5aR, complement component 5 receptor; PDE5, phosphodiesterase
    5; COX2, cyclooxygenase 2; PGE2, prostaglandin E2; CCR5, chemokine receptor 5;
    ATRA, all-trans retinoic acid; TEV, tumor-derived extracellular vesicles; RTK,
    receptor tyrosine kinase. Text in brackets represents examples of drugs targeting
    the molecule or pathway of reference. Dashed arrows and question marks underline
    controversial or not fully clarified evidence.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IL2
  - STING1
  - CSF2
  - TLR7
  - TLR8
  - FAS
  - FASN
  - BTG3
  - IL7
  - LINC02605
  - IL15
  - NR1H2
  - NR1H3
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - CARTPT
  - CASR
  - CXADR
  - PRKAR1A
  - SPG7
  - NR1I3
  - TRIM13
  - CXADRP1
  - TLR9
  - CD274
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CCR2
  - CD40
  - CTLA4
  - TAM
  - STIM1
  - Il2
  - Sting1
  - Csf2
  - Tlr7
  - Tlr8
  - Fas
  - Fasn
  - Il7
  - Il15
  - Nr1h3
  - Nr1h2
  - Trav6-3
  - Cartpt
  - Nr1i3
  - Casr
  - Cxadr
  - Rcvrn
  - Trim13
  - Arr3
  - Tlr9
  - Cd274
  - Pdcd1
  - Ccr2
  - Cd40
  - Ctla4
  - Rosiglitazone
  - Etomoxir
  - TCR
  - CpG
  - CCX782-B
  - IPI-594
  - Celecoxib
  - PGE2
  - ATRA
  - Omeprazole
  - Sutinib
  - Metformin
  - Biguanides
  - TAM
---
